Cancer, Chronic Pain
Conditions
Keywords
pain, adverse effects, safety, feasibility
Brief summary
Traditionally cancer pain is treated with long acting opioids such as morphine around the clock. However, there is no evidence that all patients have a stable pain requiring around the clock medication. So far opioids for self-administration with a rapid onset of action have not been available. Recently a nasal formulation of fentanyl (an opioid similar to morphine) was released in Europe for treatment of breakthrough pain, i.e. an unpredictable pain with short duration that breaks through the otherwise stable pain controlled with the around the clock medication. The basic idea is that this formulation may open for patient controlled analgesia of chronic cancer pain, due to the ultra rapid onset of action of nasally delivered fentanyl. This means that the patient only takes medication when in pain. This single center feasibility / safety study is the first part of a study to investigate this alternative cancer pain treatment approach.
Interventions
DRUGfentanyl
nasally, dose titrated to effect
Sponsors
St. Olavs Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Cancer patients with metastatic disease 2. Adult (older than 18 years) 3. Life expectancy of \> 3 months 4. Cancer-related pain \> 3 on an 11 point Numerical Rating Scale (NRS) 5. In the need of opioids (step II or III) 6. Able to use nasal drugs. 7. Women of child bearing potential using adequate contraception 8. Informed consent given according to applicable requirements before any trial-related activities. Trial-related activities are any procedure that would not have been performed during the routine management of the patient
Exclusion criteria
1. History of substance abuse 2. Cognitive impairment which makes the patient unable to complete questionnaires or not able to comply with the study procedures 3. Treated with MAO inhibitor within the last 14 days 4. Known hypersensitivity to study drug or specific contraindications to the study drug 5. Nasopharyngeal device such as gastric tube 6. Concomitant participation in any other trials dealing with pain with an investigational drug or device apart from cancer treatment within 14 days prior to inclusion in this trial 7. Pathological conditions of the nasal cavity as contraindication to nasal fentanyl 8. Sleep apnoea syndrome 9. Pregnant or breastfeeding women 10. Psychiatric disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| sedation/drowsiness | 10 days | scores on a 0-10 numerical rating scale; 0=none / 10=intolerable |
| nausea and vomiting | 10 days | nausea scores on a 0-10 numerical rating scale; 0=none / 10=intolerable vomiting yes/no |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| pain intensity | 10 days | scores on a 0-10 numerical rating scale; 0=none / 10=intolerable |
Countries
Norway
Outcome results
None listed